Effect of alosetron on bowel urgency and global symptoms in women with severe, diarrhea-predominant irritable bowel syndrome: Analysis of two controlled trials

Clinical Gastroenterology and Hepatology

Volumn 2, Issue 8, 2004, Pages 675-682

  Lembo, Anthony J ^a   Olden, Kevin W ^b   Ameen, Vanessa Z ^c   Gordon, Susan L ^c   Heath, Amy T ^c   Carter, Eric G ^c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MAYO CLINIC   (United States)

^c GLAXOSMITHKLINE   (United States)

Author keywords

D IBS; diarrhea predominant irritable bowel syndrome; GIS; global improvement scale; IBS; irritable bowel syndrome

Indexed keywords

ALOSETRON;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE CONTROL; DRUG EFFICACY; FECES ANALYSIS; FECES INCONTINENCE; FEMALE; HUMAN; IRRITABLE COLON; MAJOR CLINICAL STUDY; RANDOMIZED CONTROLLED TRIAL; SCREENING;

ADULT; CARBOLINES; CONSTIPATION; DEFECATION; DIARRHEA; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; IRRITABLE BOWEL SYNDROME; MIDDLE AGED; TREATMENT OUTCOME;

EID: 3542992125     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1542-3565(04)00284-8     Document Type: Article

References (29)

1. Thompson W.G., Longstreth G.F., Drossman D.A., Heaton K.W., Irvine E.J., Muller-Lissner S.A. Functional bowel disorders and functional abdominal pain. Gut. 45:1999;II43-II47
2. Gralnek I., Hays R., Kilbourne A., Naliboff B., Mayer E. The impact of IBS on health-related quality of life. Gastroenterology. 119:2000;654-660
3. Creed F., Ratcliffe J., Fernandez L., Tomenson B., Palmer S., Rigby C., Guthrie E., Read N., Thompson D. Health-related quality of life and health care costs in severe, refractory irritable bowel syndrome. Ann Intern Med. 134:2001;860-868
4. Hahn B.A., Yan S., Strassels S. Impact of irritable bowel syndrome on quality of life and resource use in the United States and United Kingdom. Digestion. 60:1999;77-81
5. Drossman D.A., Li Z., Andruzzi E., Temple R.D., Talley N.J., Thompson W.G., Whitehead W.E., Janssens J., Funch-Jensen P., Corazziari E. U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Dig Dis Sci. 38:1993;1569-1580
6. Drossman D.A., Whitehead W.E., Camilleri M. Irritable bowel syndrome a technical review for practice guideline development. Gastroenterology. 112:1997;2120-2137
7. Thompson W.G., Heaton K.W., Smyth G.T., Smyth C. Irritable bowel syndrome in general practice prevalence, characteristics, and referral. Gut. 46:2000;78-82
8. Russo M.W., Gaynes B.N., Drossman D.A. A national survey of practice patterns of gastroenterologists with comparison to the past two decades. J Clin Gastroenterol. 29:1999;339-343
9. Northcutt A., Harding J., Kong S., Hamm T., Perschy T., Heath A., Dukes G., McSorley D., Mangel A. Urgency as an endpoint in IBS. Gastroenterology. 116:1999;A1036
10. Heitkemper M., Carter E., Ameen V., Olden K., Cheng L. Women with irritable bowel syndrome differences in patients' and physicians' perceptions. Gastroenterol Nurs. 25:2002;192-200
11. Olden K., DeGarmo R.G., Jhingran P., Bagby B., Decker C., Markowitz M., Carter E., Bobbitt W., Dahdul A., DeCastro E., Gringeri L., Johanson J., Levinson L., Mula G., Poleynard G., Stoltz R.R., Truesdale R., Young D. Patient satisfaction with alosetron for the treatment of women with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol. 97:2002;3139-3146
12. Camilleri M., Northcutt A.R., Kong S., Duke G., McSorley D., Mangel A. The efficacy and safety of alosetron in female patients with irritable bowel syndrome a randomised, placebo controlled study. Lancet. 355:2000;1035-1040
13. Camilleri M., Chey W., Mayer E., Northcutt A., Heath A., Dukes G., McSorley D., Mangel A. A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant IBS. Arch Intern Med. 161:2001;1733-1740
14. Lembo T., Wright R.A., Bagby B., Decker C., Gordon S., Jhingran P., Carter E. Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol. 96:2001;2662-2670
15. Watson M.E., Lacey L., Kong S., Northcutt A.R., McSorley D., Hahn B., Mangel A.W. Alosetron improves quality of life in women with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol. 96:2001;455-459
16. Viramontes B.E., Camilleri M., McKinzie S., Pardi D.S., Burton D., Thomforde G.M. Gender-related differences in slowing colonic transit by a 5-HT3 antagonist in subjects with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol. 96:2001;2671-2676
17. Clayton N.M., Sargent R., Butler A., Gale J., Maxwell M.P., Hunt A.A., Barrett V.J., Cambridge D., Bountra C., Humphrey P.P. The pharmacological properties of the novel selective 5-HT3 receptor antagonist, alosetron, and its effects on normal and perturbed small intestinal transit in the fasted rat. Neurogastroenterol Motil. 11:1999;207-217
18. Delvaux M., Louvel D., Mamet J.P., Campos-Oriola R., Frexinos J. Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome. Aliment Pharmacol Ther. 12:1998;849-855
19. 3 antagonist alosetron on basal and cholera toxin-induced secretion in the human jejunum a segmental perfusion study. Aliment Pharmacol Ther. 11:1997;1109-1114
20. Berman S.M., Chang L., Suyenobu B., Derbyshire S.W., Stains J., Fitzgerald L., Mandelkern M., Hamm L., Vogt B., Naliboff B.D., Mayer E.A. Condition-specific deactivation of brain regions by 5-HT3 receptor antagonist Alosetron. Gastroenterology. 123:2002;969-977
21. Mayer E.A., Berman S., Derbyshire S.W., Suyenobu B., Chang L., Fitzgerald L., Mandelkern M., Hamm L., Vogt B., Naliboff B.D. The effect of the 5-HT3 receptor antagonist, alosetron, on brain responses to visceral stimulation in irritable bowel syndrome patients. Aliment Pharmacol Ther. 16:2002;1357-1366
22. Lotronex Product Information [on-line]. 2002;GlaxoSmithKline, Research Triangle Park, NC. Available at: http://us.gsk.com/products/assets/us_lotronex. pdf
23. Harding J.P., Hamm L.R., Ehsanullah R., Heath A.T., Sorrells S.C., Haw J., Dukes G.E., Wolfe S.G., Mangel A.W., Northcutt A.R. Use of a novel electronic data collection system in multicenter studies of irritable bowel syndrome. Aliment Pharmacol Ther. 11:1997;1073-1076
24. Van Elteren P. On the combination of independent two sample tests of Wilcoxon. Bulletin Int Stat Inst. 37:1960;351-361
25. Hollander M., Wolfe D. Nonparametric statistical methods. 1973;John Wiley and Sons, Inc
26. Stokes E., Davis C., Koch G. Categorical data analysis using the SAS system. 1995;105-119 SAS Institute, Inc, Cary, NC
27. Veldhuyzen van Zanten S.J., Talley N.J., Bytzer P., Klein K.B., Whorwell P.J., Zinsmeister A.R. Design of treatment trials for functional gastrointestinal disorders. Gut. 45:(Suppl 2):1999;II69-II77
28. Gordon S., Ameen V., Bagby B., Shahan B., Jhingran P., Carter E. Validation of the irritable bowel syndrome global improvement scale an integrated symptom endpoint for assessing treatment efficacy. Dig Dis Sci. 48:2003;1317-1323
29. Wolfe S.G., Chey W.Y., Washington M.K., Harding J., Heath A., McSorley D., Dukes G.E., Hunt C.M. Tolerability and safety of alosetron during long-term administration in female and male irritable bowel syndrome patients. Am J Gastroenterol. 96:2001;803-811